Methods, compositions and articles of manufacture for contributing to the treatment of cancers
View Patent ↗Methods, compositions and articles of manufacture for contributing to the treatment of cancers, including solid tumors, are disclosed. The methods, compositions and articles of manufacture can utilize an endothelin B agonist (ET B ) to enhance the delivery and resulting efficacy of a chemotherapeutic agent.
1. An article of manufacture comprising: (a) a packaged composition comprising an IRL-1620, (b) a packaged composition comprising a chemotherapeutic agent; (c) an insert providing instructions for the administration of (a) and (b) for the treatment of a solid tumor in a mammal, wherein said solid tumor is a prostate tumor or a melanoma tumor; and (d) a container for (a), (b), and (c).
2. The article of manufacture according to claim 1 , wherein said chemotherapeutic agent is selected from the group consisting of adriamycin, camptothecin, carboplatin, cisplatin, daunorubicin, doxorubicin, alpha interferon, beta interferon, gamma interferon, interleukin 2, irinotecan, docetaxel, paclitaxel, topotecan, and mixtures thereof.
3. The article of manufacture according to claim 1 , wherein said chemotherapeutic agent is paclitaxel.
4. An article of manufacture comprising: (a) a packaged composition comprising an IRL-1620; (b) a packaged composition comprising a chemotherapeutic agent; (c) an insert providing instructions for a simultaneous or sequential administration of (a) and (b) to treat a solid tumor in a mammal, wherein said solid tumor is a prostate tumor or a melanoma tumor; and (d) a container for (a), (b), and (c).
5. The article of manufacture according to claim 4 , wherein said chemotherapeutic agent is selected from the group consisting of adriamycin, camptothecin, carboplatin, cisplatin, daunorubicin, doxorubicin, alpha interferon, beta interferon, gamma interferon, interleukin 2, irinotecan, docetaxel, paclitaxel, topotecan, and mixtures thereof.
6. The article of manufacture according to claim 4 , wherein said chemotherapeutic agent is selected from the group consisting of paclitaxel, doxorubicin, 5-fluorouracil, and combinations thereof.
7. The article of manufacture according to claim 4 , wherein said chemotherapeutic agent is paclitaxel.
8. The article of manufacture according to claim 4 , wherein said chemotherapeutic agent is cisplatin.
9. An article of manufacture comprising a composition comprising an IRL-1620 and a chemotherapeutic agent, and instructional information directing the administration of said composition with a chemotherapeutic agent to treat a solid tumor, wherein said solid tumor is a prostate tumor or a melanoma tumor.
10. The article of manufacture according to claim 9 , wherein said chemotherapeutic agent is selected from the group consisting of adriamycin, camptothecin, carboplatin, cisplatin, daunorubicin, doxorubicin, alpha interferon, beta interferon, gamma interferon, interleukin 2, irinotecan, docetaxel, paclitaxel, topotecan, 5-fluorouracil, and combinations thereof.
11. The article of manufacture according to claim 9 , wherein said chemotherapeutic agent is selected from the group consisting of paclitaxel, doxorubicin, 5-fluorouracil, and combinations thereof.
12. The article of manufacture according to claim 9 , wherein said chemotherapeutic agent is paclitaxel.
13. The article of manufacture according to claim 9 , wherein said chemotherapeutic agent is cisplatin.
14. An article of manufacture comprising: (a) a packaged composition comprising an IRL-1620; (b) a packaged composition comprising a chemotherapeutic agent; (c) an insert providing instructions for administration of (a) and (b) to treat a prostate tumor in a mammal; and (d) a container for (a), (b), and (c).
15. An article of manufacture comprising: (a) a packaged composition comprising an IRL-1620; (b) a packaged composition comprising a paclitaxel; (c) an insert providing instructions for a simultaneous or sequential administration of (a) and (b) to treat a prostate tumor in a mammal; and (d) a container for (a), (b), and (c).
16. An article of manufacture comprising: (a) a packaged composition comprising an IRL-1620; (b) a packaged composition comprising a chemotherapeutic agent; (c) an insert providing instructions for administration of (a) and (b) to treat a melanoma tumor in a mammal, and (d) a container for (a), (b), and (c).
17. An article of manufacture comprising: (a) a packaged composition comprising an IRL-1620; (b) a packaged composition comprising a cisplatin; (c) an insert providing instructions for a simultaneous or sequential administration of (a) and (b) to treat a melanoma tumor in a mammal; and (d) a container for (a), (b), and (c).